This GLP-1 drug helped people maintain their weight loss in a clinical trial — even for those taking it once a month

Viking Therapeutics is developing VK2735, a GLP-1/GIP drug that could compete with Eli Lilly’s Zepbound. Its stock is soaring.

Image from the linked report: This GLP-1 drug helped people maintain their weight loss in a clinical trial — even for those taking it once a month.Credit: MarketWatch Thumbnail shown with attribution and outbound source link; VINI does not claim ownership or republish the original article body. Image source Image shown with attribution and an outbound source link; VINI does not claim ownership or republish the original article body.

Reading time1 min

coverage / Wire report

References1 public source

Open references

Reader responseTechnology

Right of reply / send a tip

SupportDonate

Fund future reporting

Why it mattersTechnology

Viking Therapeutics is developing VK2735, a GLP-1/GIP drug that could compete with Eli Lilly’s Zepbound. Its stock is soaring.

What to know1 source

Check the original link, updates, and responses when a detail is contested.

Keep readingfinance

Open topic or search related wording such as records, sources, agencies, dates, and locations.

Vinita Duniphin Technology Wire report

What happened

According to MarketWatch’s source item, This GLP-1 drug helped people maintain their weight loss in a clinical trial — even for those taking it once a month, Viking Therapeutics is developing VK2735, a GLP-1/GIP drug that could compete with Eli Lilly’s Zepbound. Its stock is soaring.

Context

The development sits in VINI’s Technology file for readers following technology, science, product policy, markets, infrastructure, and the public consequences of innovation. The original report is linked so readers can check the source account, follow later updates, and compare new coverage against the first published record. The source item is dated 2026-09-22T15:46:00+00:00.

What to watch

Open questions include whether primary sources issue follow-up statements, whether local or market impacts become clearer, and whether additional reporting changes the timeline or adds material context.

Source

Primary source: This GLP-1 drug helped people maintain their weight loss in a clinical trial — even for those taking it once a month via MarketWatch. VINI cites and links the source; it does not reproduce the publisher’s full article text without rights clearance.

Keep following

This file can keep developing

vininews.com uses reader tips, public records, right-of-reply requests, corrections, and follow-up reporting to keep important stories current.

SubscribeGet the next update Send recordsShare documents or leads RespondRequest comment or reply DonateSupport reporting costs

Support and subscriptions never buy coverage, placement, suppression, or corrections.

This VINI report keeps the original publisher link available and does not republish third-party article bodies without rights clearance. 1 reference listed.

Reader comments

Moderated discussion

Account access

Comments are open to authenticated approved accounts, screened for spam and abuse, and published only after newsroom moderation unless editors change the story control.

Loading comments.

No approved comments yet.

Substantive, civil comments can be submitted by approved account holders.